Brad Watts, senior vice president at the U.S. Chamber of Commerce’s Global Innovation Policy Center (GIPC), oversees the center’s day-to-day operations. He also leads the development and implementation of the Chamber’s U.S. and global intellectual property (IP) agenda to foster a political, legal, and economic environment where innovators and creators can invest in the next big thing for the benefit of Americans and the world.
Watts previously served as the Republican chief counsel on the Senate Judiciary Committee Subcommittee on Intellectual Property. There he was responsible for planning and implementing Senator Thom Tillis’ (R-NC) and the Republican party’s legislative portfolio on all aspects of IP law.
In the 116th Congress, when Senator Tillis was chairman of the subcommittee, Watts served as majority chief counsel and staff director for the Senate Judiciary Committee Subcommittee on Intellectual Property. He was responsible for implementing the senator’s legislative and oversight agenda on all aspects of America’s innovation economy.
During Watts’ tenure as majority chief counsel, the subcommittee held 17 legislative and oversight hearings and multiple staff briefings on IP issues, ranging from the state of patent eligibility law in America to reforming the Digital Millennium Copyright Act of 1998. Under his leadership, the subcommittee passed the CASE Act, the Trademark Modernization Act, and the Protecting Lawful Streaming Act, three landmark bills that collectively represent the largest changes to IP law since the Leahy-Smith America Invents Act.
Earlier, Watts was chief immigration counsel to then-Senate Judiciary Committee Chairman Chuck Grassley (R-IA). He began his career with former Senator Jeff Sessions (R-AL) as a legislative counsel on the Subcommittee on Immigration and the National Interest, handling civil rights and civil liberties law, general tort law, bankruptcy, telecommunications, and IP issues for the senator.
Medicare's New Drug Price Mandate: Healthcare & Innovation Implications
Lisa Larrimore Ouellette, Adam Mossoff, Dan Troy, Brad Watts
On January 17, the Biden-Harris Administration added 15 new drugs, including Ozempic, to the list of...
Topics
The IRA’s Drug Price Caps Threaten Patient Health by Disincentivizing New Research
The Drug Price Negotiation Program passed—as part of the Inflation Reduction Act (IRA)—along partisan lines...
Is There a Business Case for Racial and Ethnic Diversity for Corporate Leadership?
Sanjai Bhagat
An influential 2015 McKinsey study claims a business case for racial and ethnic diversity in...
President Trump's "One-In-Two-Out" Executive Order - Podcast
Susan E. Dudley, Jitinder Kohli
President Trump took a step toward fulfilling his campaign promise to cut regulations last week...
President Trump's "One-In-Two-Out" Executive Order
TeleforumPending Litigation and the New Administration - Podcast
Steven Gill Bradbury, William S. Consovoy
Given the size and scope of the federal government, many agency regulations, guidance documents, and...
Giveth & Taketh Away? - Podcast
David H. Thompson
After a bailout that arguably helped keep them afloat, the United States government has effectively...
Consumer Financial Protection Bureau Update - April 2015 - Podcast
Julius L. Loeser, Todd J. Zywicki
Members of the Federalist Society’s Financial Services & E-Commerce Practice Group Executive Committee provided an...
Net Neutrality vs. Net Reality: Why an Evidence-Based Approach to Enforcement, And Not More Regulation, Could Protect Innovation on the Web
Maureen K. Ohlhausen
Related Links: Senate Committee on Commerce, Science, and Transportation, Hearing on “Network Neutrality” (testimony of...
The Bailout